Increased Medication Error Analysis Is Key To Improving Drug Safety – Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA should enhance its post-market monitoring of drug safety through greater surveillance of medication errors, a member of FDA's Drug Safety & Risk Management Advisory Committee said during a May 19 meeting in Silver Spring, Md
You may also be interested in...
DSaRM meeting
FDA's Drug Safety & Risk Management Advisory Committee will convene Feb. 10 to "receive updates on the Drug Safety Oversight Board and agency actions" on COX-2 inhibitors, an announcement in the Federal Register Jan. 6 states. The committee, which will meet from 8 am-3 pm in Gaithersburg, Md., also will be briefed on developments in the Office of Drug Safety. Since the September 2004 market withdrawal of Merck's Vioxx, FDA has hosted a three-day meeting on use of COX-2s and other NSAIDs, as well as required a black box label statement for Pfizer's Celebrex. During a meeting in May, members of the Drug Safety committee advised that FDA make its drug safety process more transparent and consider placing drug safety experts on each of its advisory committees (1"The Tan Sheet" May 30, 2005, p. 9)...
DSaRM meeting
FDA's Drug Safety & Risk Management Advisory Committee will convene Feb. 10 to "receive updates on the Drug Safety Oversight Board and agency actions" on COX-2 inhibitors, an announcement in the Federal Register Jan. 6 states. The committee, which will meet from 8 am-3 pm in Gaithersburg, Md., also will be briefed on developments in the Office of Drug Safety. Since the September 2004 market withdrawal of Merck's Vioxx, FDA has hosted a three-day meeting on use of COX-2s and other NSAIDs, as well as required a black box label statement for Pfizer's Celebrex. During a meeting in May, members of the Drug Safety committee advised that FDA make its drug safety process more transparent and consider placing drug safety experts on each of its advisory committees (1"The Tan Sheet" May 30, 2005, p. 9)...
DSaRM meeting
FDA's Drug Safety & Risk Management Advisory Committee will convene Feb. 10 to "receive updates on the Drug Safety Oversight Board and agency actions" on COX-2 inhibitors, an announcement in the Federal Register Jan. 6 states. The committee, which will meet from 8 am-3 pm in Gaithersburg, Md., also will be briefed on developments in the Office of Drug Safety. Since the September 2004 market withdrawal of Merck's Vioxx, FDA has hosted a three-day meeting on use of COX-2s and other NSAIDs, as well as required a black box label statement for Pfizer's Celebrex. During a meeting in May, members of the Drug Safety committee advised that FDA make its drug safety process more transparent and consider placing drug safety experts on each of its advisory committees (1"The Tan Sheet" May 30, 2005, p. 9)...